Inclusion Criteria:

- This study will evaluate MK0457 in patients with CML (chronic myelogenous leukemia)
and Ph+ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia)

- Patients must have adequate organ function

- Patients must have documented T315I mutation

Exclusion Criteria:

- Patients within 3 months of allogeneic bone marrow transplant or not fully recovered
from previous anti-leukemia therapy

- Patients with uncontrolled congestive heart failure

- Patients with active or uncontrolled infection or active Hepatitis B or C

- Patients with known HIV positivity or AIDS related illness

- Patients with currently active second malignancy, other than non-melanoma skin
cancer.